## Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 4

ORAMED Form 4 April 11, 20	PHARMACEUTI	CALS IN	C.							
	ЛЛ								PPROVAL	
FORM	UNITED	STATES		RITIES A Ashington			COMMISSIO	N OMB Number:	3235-0287	
Check t if no los subject Section Form 4 Form 5 obligati may co	nger to 16. or Filed pur ons Section 17(	suant to S (a) of the F	F CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES Section 16(a) of the Securities Exchange Act of 1934, Public Utility Holding Company Act of 1935 or Sectio					Estimated burden hou response	Estimated average burden hours per response 0.5	
<i>See</i> Inst 1(b).		30(h)	of the I	nvestment	: Compan	y Act of 1	940			
(Print or Type	Responses)									
1. Name and Address of Reporting Person <u>*</u> KIDRON NADAV			2. Issuer Name and Ticker or Trading Symbol ORAMED PHARMACEUTICALS INC. [ORMP]			5. Relationship of Reporting Person(s) to Issuer (Check all applicable)				
(Last) (First) (Middle) 12 ELIEZER HAGADOL ST.			3. Date of Earliest Transaction (Month/Day/Year) 04/09/2014			_X_ Director _X_ 10% Owner _X_ Officer (give title Other (specify below)				
(Street)			4. If Amendment, Date Original Filed(Month/Day/Year)			<ul><li>6. Individual or Joint/Group Filing(Check</li><li>Applicable Line)</li><li>_X_ Form filed by One Reporting Person</li></ul>				
JERUSAL	EM, L3 9359038						Form filed by Person	More than One R	eporting	
(City)	(State)	(Zip)	Tab	ole I - Non-l	Derivative	Securities A	cquired, Disposed	of, or Beneficia	lly Owned	
1.Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	Execution I any	Date, if	3. Transactio Code (Instr. 8) Code V		(A) or of (D)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)	
Reminder: Re	port on a separate line	e for each cla	ass of sec	urities hene	ficially own	ned directly	or indirectly			
A standard Re				arries bene.	Perso inform requir	ns who rest nation cont ed to resp ys a curre	spond to the colle tained in this form ond unless the fo ntly valid OMB co	n are not orm	SEC 1474 (9-02)	

 Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned

 (e.g., puts, calls, warrants, options, convertible securities)

1. Title of	2.	3. Transaction Date	3A. Deemed	4.	5. Number of	6. Date Exercisable and	7. Title and Amount of
Derivative	Conversion	(Month/Day/Year)	Execution Date, if	Transacti	orDerivative	Expiration Date	Underlying Securities
Security	or Exercise		any	Code	Securities	(Month/Day/Year)	(Instr. 3 and 4)

8 E S

## Edgar Filing: ORAMED PHARMACEUTICALS INC. - Form 4

(Instr. 3)	Price of Derivative Security	(Month/Day/Year	) (Instr. 8)	Acquired or Dispose (D) (Instr. 3, 4 and 5)	ed of				(
			Code V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	\$ 12.45	04/09/2014	А	47,134		<u>(1)</u>	04/09/2024	Common Stock	47,134

## **Reporting Owners**

<b>Reporting Owner Name / Address</b>	Relationships						
	Director	10% Owner	Officer	Other			
KIDRON NADAV 12 ELIEZER HAGADOL ST. JERUSALEM, L3 9359038	Х	Х	President and CEO				
Signatures							

/s/ Nadav Kidron	04/11/2014		
<u>**</u> Signature of Reporting Person	Date		

## **Explanation of Responses:**

- \* If the form is filed by more than one reporting person, *see* Instruction 4(b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) The Stock Option will vest with respect to 15,710 shares on April 30, 2014 and with respect to 3,928 shares on the last day of each month thereafter.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure. Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

(